Ruben A. Mesa
Impact in
- Genetics top 0.01%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
- Genetics 595
- Myeloproliferative Neoplasms: Diagnosis and Treatment 584
- Hemoglobinopathies and Related Disorders 50
- Hematology 405
- Chronic Myeloid Leukemia Treatments 244
- Acute Myeloid Leukemia Research 189
- Multiple Myeloma Research and Treatments 57
- Platelet Disorders and Treatments 18
- Co-authors
- Ayalew Tefferi (141 shared papers)Srđan Verstovšek (135 shared papers)Animesh Dev Pardanani (53 shared papers)Alessandro Maria Vannucchi (77 shared papers)Claire Harrison (101 shared papers)Francesco Passamonti (49 shared papers)Francisco Cervantes (26 shared papers)Terra L. Lasho (30 shared papers)
- Journals
- Blood (209 papers)Leukemia Research (29 papers)Haematologica (27 papers)Leukemia (26 papers)British Journal of Haematology (22 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Ruben A. Mesa
673 papers receiving 35.5k citations
Ruben A. Mesa's Hit Papers
Peers
Comparison fields: 5 of 166
- Genetics 27.7k
- Hematology 18.8k
- Rheumatology 9.0k
- Molecular Biology 13.9k
- Oncology 4.1k
Countries citing papers authored by Ruben A. Mesa
This map shows the geographic impact of Ruben A. Mesa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruben A. Mesa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruben A. Mesa more than expected).
Fields of papers citing papers by Ruben A. Mesa
This network shows the impact of papers produced by Ruben A. Mesa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruben A. Mesa. The network helps show where Ruben A. Mesa may publish in the future.
Co-authors
The 25 scholars most cited alongside Ruben A. Mesa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 698 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Hit paper breakdown → | 2005 | 2544 |
| 2 | A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Hit paper breakdown → | 2012 | 1715 |
| 3 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Hit paper breakdown → | 2020 | 1331 |
| 4 | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Hit paper breakdown → | 2008 | 1000 |
| 5 | Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Hit paper breakdown → | 2010 | 992 |
| 6 | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Hit paper breakdown → | 2006 | 877 |
| 7 | Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera Hit paper breakdown → | 2015 | 723 |
| 8 | Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Hit paper breakdown → | 2007 | 703 |
| 9 | Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet Hit paper breakdown → | 2011 | 646 |
| 10 | Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet Hit paper breakdown → | 2018 | 438 |
| 11 | 2007 | 418 | |
| 12 | Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis Hit paper breakdown → | 2015 | 405 |
| 13 | 2012 | 360 | |
| 14 | 2009 | 359 | |
| 15 | 2017 | 359 | |
| 16 | 2006 | 333 | |
| 17 | 2013 | 331 | |
| 18 | 2004 | 316 | |
| 19 | 2018 | 314 | |
| 20 | 2017 | 299 |
About Ruben A. Mesa
Ruben A. Mesa is a scholar working on Genetics, Hematology, Rheumatology, Molecular Biology and Oncology, having authored 698 papers that have together received 36.4k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (584 papers), Chronic Myeloid Leukemia Treatments (244 papers), Acute Myeloid Leukemia Research (189 papers), Kruppel-like factors research (160 papers), Eosinophilic Disorders and Syndromes (140 papers), Multiple Myeloma Research and Treatments (57 papers), Hemoglobinopathies and Related Disorders (50 papers) and Platelet Disorders and Treatments (18 papers). The work is most often cited by research in Genetics (27.7k citations), Hematology (18.8k citations), Rheumatology (9.0k citations), Molecular Biology (13.9k citations) and Oncology (4.1k citations). Ruben A. Mesa has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Ayalew Tefferi, Srđan Verstovšek, Animesh Dev Pardanani, Alessandro Maria Vannucchi, Claire Harrison, Francesco Passamonti, Francisco Cervantes, Terra L. Lasho, Curtis A. Hanson and Georgene S. Schroeder. Their work appears in journals such as Blood, Leukemia Research, Haematologica, Leukemia and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.